Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.
Genetically Targeted
Designed to reduce craving to effectively curb alcohol intake in those patients with the genetics expected to indicate a likely response to treatment with AD04
BRINGS 20+ YEAR TRACK RECORD OF CLINICAL USE
To date, clinical testing of AD04 has shown it to have a positive safety and tolerability profile with side effects similar to placebo.
Oral daily dosing
Our product candidate is intended to be easy to use since it is administered orally.
AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption
Email Alerts
SIGN UP TODAYLatest Tweets
Drinking is a slippery slope, especially if it is being used as an escape. #MedicinesForAddictions #AUD #OUD #JohnnyDepp
Johnny Depp on ‘poisoning’ himself with limitless drugs and alcohol
Johnny Depp had earlier confessed that his alcoholism was not ‘for fun’
ow.ly
With less treatment available, and fewer people in treatment, more will go back to old habits. #MedicinesForAddictions #AUD #OUD #lockdown
Drug and #alcohol referrals down 57% in Wales since #lockdown. The problem is not getting better, but help is no longer as available. ... #MedicinesForAddictions #AUD #OUD
Lockdown drug and alcohol referrals down 57%
A drug charity says it has seen a "significant reduction" in addict numbers making contact.
www.bbc.co.uk
AD04 Ready to Enter Phase 3 in Targeted Groups
Adial is preparing to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.